Detection of Ferritin Expression in Soft Tissue Sarcomas With MRI: Potential Implications for Iron Metabolic Therapy
Cancer cells often have altered iron metabolism relative to non-malignant cells with increased transferrin receptor and ferritin expression. Targeting iron regulatory proteins as part of a cancer therapy regimen is currently being investigated in various malignancies. Anti-cancer therapies that expl...
Saved in:
Published in | The Iowa orthopaedic journal Vol. 42; no. 1; pp. 255 - 262 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The University of Iowa
01.06.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1555-1377 1541-5457 1555-1377 |
Cover
Summary: | Cancer cells often have altered iron metabolism relative to non-malignant cells with increased transferrin receptor and ferritin expression. Targeting iron regulatory proteins as part of a cancer therapy regimen is currently being investigated in various malignancies. Anti-cancer therapies that exploit the differences in iron metabolism between malignant and non-malignant cells (e.g. pharmacological ascorbate and iron chelation therapy) have shown promise in various cancers, including glioblastoma, lung, and pancreas cancers. Non-invasive techniques that probe tissue iron metabolism may provide valuable information for the personalization of iron-based cancer therapies. T
* mapping is a clinically available MRI technique that assesses tissue iron content in the heart and liver. We aimed to investigate the capacity of T
* mapping to detect iron stores in soft tissue sarcomas (STS).
In this study, we evaluated T
* relaxation times ex vivo in five STS samples from subjects enrolled on a phase Ib/IIa clinical trial combining pharmacological ascorbate with neoadjuvant radiation therapy. Iron protein expression levels (ferritin, transferrin receptor, iron response protein 2) were evaluated by Western blot analysis. Bioinformatic data relating clinical outcomes in STS patients and iron protein expression levels were evaluated using the KMplotter database.
There was a high level of inter-subject variability in the expression of iron protein and T
* relaxation times. We identified that T
* relaxation time is capable of accurately detecting ferritin-heavy chain expression (r = -0.96) in these samples. Bioinformatic data acquired from the KMplot database revealed that transferrin receptor and iron-responsive protein 2 may be negative prognostic markers while ferritin expression may be a positive prognostic marker in the management of STS.
These data suggest that targeting iron regulatory proteins may provide a therapeutic approach to enhance STS management. Additionally, T
* mapping has the potential to be used a clinically accessible, non-invasive marker of STS iron regulatory protein expression and influence cancer therapy decisions that warrants further investigation.
. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures: The authors report no potential conflicts of interest related to this study. Sources of Funding: This work was supported by the University of Iowa Sarcoma Multidisciplinary Oncology Group, NIH grants T32 CA078586, P01 CA217797, P01 CA244091, R01 CA169046, R21 CA256301, and the Gateway for Cancer Research grant G-17-1500. Core facilities were supported in part by the Carver College of Medicine and the Holden Comprehensive Cancer Center, NIH P30 CA086862. |
ISSN: | 1555-1377 1541-5457 1555-1377 |